Latest Breaking News On - டைனோ சிகிச்சை - Page 1 : comparemela.com
A biotech startup raises $117M to deliver gene therapies in a new way
biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Manufacturing Gene Therapy | BioPharma Dive
biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration
May 11, 2021
Share
Biogen will partner with Capsigen to engineer novel adeno-associated virus (AAV) capsids for gene therapies designed to treat CNS and neuromuscular disorders, through a strategic research collaboration that could generate more than $1.3 billion for Capsigen.
The companies said they will create and identify novel AAV capsids tailored to meet disease-specific transduction profiles through their collaboration, designed to combine Capsigen’s Transcription-Dependent Directed Evolution (TRADE™) platform and associated technologies with Biogen’s discovery, development, manufacturing, and commercialization capabilities.
Capsigen’s technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline.
Dive Brief:
In its latest investment into the field of gene therapy, Biogen has licensed technology that it believes could help create new treatments for central nervous system and neuromuscular disorders.
The deal with Capsigen, a Washington-based biotech, has Biogen paying $15 million at the start and potentially up to $1.3 billion later on, provided certain research, development and sales milestones are hit. Capsigen is also eligible for royalties on future net sales on any resulting products that use its technology.
Capsigen specializes in developing adeno-associated virus vectors, which are used like microscopic shuttles to deliver genetic medicine into human cells. The deal with Biogen tasks Capsigen with creating new capsids the outer coating which protects the genetic payload that are customized to target specific diseases.
Published May 6, 2021 Permission granted by Eric Kelsic / Dyno Therapeutics
Dyno Therapeutics, a Harvard University spinout working to improve gene therapy, is expanding with $100 million in new funding from tech investor Andreessen Horowitz and several other venture firms.
Since officially launching a year ago, Dyno has struck deals with Novartis, Roche and Sarepta Therapeutics to aid their efforts to develop more efficient delivery of gene therapy. But even after doubling in size to 50 employees, the company hasn t been able to keep up with demand for its services, CEO Eric Kelsic said in an interview. Even though it s in the very beginning, we just had so many folks who want to partner with us, said Kelsic. This is really to meet the demand that we ve seen for partnering and to enable us to both expand our [existing] partnerships, as well as to work with new partners.
vimarsana © 2020. All Rights Reserved.